- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Brukinsa
Synonyms :
zanubrutinib
Class :
Antineoplastics and Tyrosine Kinase Inhibitor
160
mg
Oral
twice a day
Capsule
Continue the therapy until disease progression or unacceptable toxicity occurs
Dose Adjustments
Mild to severe: No adjustment recommended
Safety and efficacy are not studied
Refer adult dosing
CYP3A4 Inhibitors (Moderate) may increase the serum concentration when combined with Zanubrutinib
CYP3A4 Inhibitors (Moderate) may increase the serum concentration when combined with Zanubrutinib
CYP3A4 Inhibitors (Moderate) may increase the serum concentration when combined with Zanubrutinib
CYP3A4 Inhibitors (Moderate) may increase the serum concentration when combined with Zanubrutinib
CYP3A4 Inhibitors (Moderate) may increase the serum concentration when combined with Zanubrutinib
zanubrutinib: they may diminish the serum concentration of CYP3A4 Inducers
zanubrutinib: they may diminish the serum concentration of CYP3A4 Inducers
zanubrutinib: they may diminish the serum concentration of CYP3A4 Inducers
zanubrutinib: they may diminish the serum concentration of CYP3A4 Inducers
zanubrutinib: they may diminish the serum concentration of CYP3A4 Inducers
zanubrutinib: they may enhance the serum concentration of CYP3A Inhibitors
zanubrutinib: they may enhance the serum concentration of CYP3A Inhibitors
zanubrutinib: they may enhance the serum concentration of CYP3A Inhibitors
zanubrutinib: they may enhance the serum concentration of CYP3A Inhibitors
zanubrutinib: they may enhance the serum concentration of CYP3A Inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 Inhibitors
when both drugs are combined, there may be increase in the effect of immunosuppressants
the effect of zanubrutinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
CYP3A strong enhancers of the small intestine may reduce the bioavailability of zanubrutinib
CYP3A4 inducers decrease the concentration of zanubrutinib in serum
when both drugs are combined, there may be a decrease in the therapeutic effect
aminosalicylic acid derivatives
it may increase the effect of myelosuppressive agents
immunosuppressants may reduce the therapeutic effect of pneumococcal vaccines
it increases the effect of antiplatelet agents
it increases the effect of antiplatelet agents
it increases the effect of antiplatelet agents
it increases the effect of antiplatelet agents
it increases the effect of antiplatelet agents
may have an increasingly adverse effect when combined with anticoagulants
may have an increasingly adverse effect when combined with anticoagulants
may have an increasingly adverse effect when combined with anticoagulants
may have an increasingly adverse effect when combined with anticoagulants
may have an increasingly adverse effect when combined with anticoagulants
It may enhance the risk of bleeding by affecting coagulation when combined with omega-3 carboxylic acids
it increases the effect of antiplatelet agents
it increases the effect of antiplatelet agents
zanubrutinib: they may increase the antiplatelet effect of antiplatelet agents
zanubrutinib: they may increase the antiplatelet effect of antiplatelet agents
zanubrutinib: they may increase the antiplatelet effect of antiparasitic agents
zanubrutinib: they may increase the antiplatelet effect of antiparasitic agents
zanubrutinib: they may increase the antiplatelet effect of antiparasitic agents
zanubrutinib: they may increase the antiplatelet effect of antiparasitic agents
idelalisib increases the effect or level of zanubrutinib by altering the intestinal/hepatic CYP3A4 metabolism
metronidazole enhances the effect of zanubrutinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
may enhance the toxic effect of anti-coagulants
Adverse drug reactions:
Frequency defined
>10%:
hypokalemia
increased serum glucose
increased serum potassium
Abdominal pain
constipation
diarrhea
nausea
vomiting
Urinary tract infection
Pregnancy warnings:
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first trimester or the later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits
Category X: Drugs listed in this category outweigh risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient Information Leaflet
Generic Name: zanubrutinib (Rx)
Pronounced: za-nu-bru-ti-nib
Why do we use zanubrutinib?
zanubrutinib is an anticancer drug used to treat mantle cell lymphoma and inhibit the growth and spread of cancer cells.
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra
